OverviewChartNewsTraderScreen

Soc. Generale Knock-Out AYJ/  DE000SU5PU31  /

Frankfurt Zert./SG
9/20/2024  4:50:47 PM Chg.+0.110 Bid5:35:48 PM Ask- Underlying Strike price Expiration date Option type
4.050EUR +2.79% -
Bid Size: -		 -
Ask Size: -		 VALNEVA SE EO... 6.6238 EUR 12/31/2078 Put
GlobeNewswire 9/3 Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
GlobeNewswire 8/13 Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 8/1 Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’...
GlobeNewswire 7/22 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the Wo...
GlobeNewswire 7/17 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
GlobeNewswire 7/1 Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ...
GlobeNewswire 6/26 Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Direct...
GlobeNewswire 6/24 Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
GlobeNewswire 6/5 Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Co...
GlobeNewswire 6/4 Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
GlobeNewswire 6/3 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire 5/31 Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
GlobeNewswire 5/21 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
GlobeNewswire 5/13 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire 5/7 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 3/26 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
GlobeNewswire 3/25 Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire 3/21 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire 3/20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 3/18 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire 3/4 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire 2/29 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire 2/15 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 2/5 Valneva Announces Sale of Priority Review Voucher for $103 Million
GlobeNewswire 1/10 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine